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2Abstract
Cancer cells must alter their metabolism in order to satisfy the demands of necessary energy
and cellular building blocks. These metabolic alterations are mediated by many oncogenic
changes that affect cellular signalling pathways, which result in sustained cell growth and
proliferation. Recently, metabolomics, has received great attention in the field of cancer
research and as the essential metabolic pathways that drive tumour growth and progression are
determined, the possibilities of new targets for therapeutic intervention are opened. More
specifically, as breast cancer is a heterogeneous disease there is growing evidence that
differences in metabolic changes exist between molecular subtypes.
In this review, the most recent findings in breast cancer cell metabolism are discussed, with
particular emphasis on glutamine and its transporters which is considered one of the key amino
acids fuelling cancer growth. Furthermore, the metabolic differences between the molecular
subtypes of breast cancer are examined, highlighting the clinical utility for breast cancer
diagnosis and treatment.
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3Introduction
One of the hallmarks of cancer 1, altered metabolic profile, has been demonstrated for many
years, and the significance of cancer metabolism and its exploitation for anticancer therapy has
recently attracted great attention. Relentless proliferation of cancer cells is metabolically
demanding, requiring ATP generation for the necessary energy and production of metabolic
intermediates. The latter are the precursors for cellular ‘building blocks’, in the form of
nucleotides for DNA/ RNA, amino acids for proteins and fatty acids for lipids. In addition to
increasing the amount of metabolites the cells require, cancer cells actively alter the way
nutrients are used. This adaptation process has been termed “metabolic transformation” 2.
In order to fuel the aberrant proliferation, cancer cells reprogram their glucose metabolism.
Glycolysis is normally elevated under anaerobic conditions and is the major source of energy
in malignant tumours, even with the presence of oxygen; a phenomenon known as aerobic
glycolysis or the Warburg effect 3, 4, where glucose is mainly converted to lactate rather than
engaging in the mitochondrial oxidative phosphorylation. Glutamine is the second primary
metabolite to nourish cancer cell proliferation. Although it is a non-essential amino acid in
normal cells, glutamine becomes essential to the proliferative neoplastic cells and certain
cancer cell types become “addicted” to glutamine as they fail to grow or proliferate in its’
absence 5. Glutamine metabolism not only assists ATP production, it is also essential for
biosynthesis of nucleotides, lipid and proteins in addition to its role as a regulator for
redox balance 6. SLC1A5 (ASCT2) and SLC7A5 (LAT1) are the key cellular glutamine
transporters which show higher affinity for their substrates and both are up-regulated in
a variety of cancers where their expression pattern is comparable 7.
Changes in glutamine metabolism are controlled by activated oncogenes (e.g. MYC) and/or
loss of tumour suppressors, e.g. Retinoblastoma (Rb), which can enhance the uptake and
4utilisation via up-regulation of cellular transporters and enzymes supporting tumour replication
and giving rise to aggressive cancer phenotypes 8 9.
Breast cancer (BC) is a heterogeneous disease characterised by different morphology,
clinical outcome and response to treatment. Based on the gene expression profile, BC can
be classified into different molecular subtypes; luminal A (ER and/or PR receptor
positive, HER2 negative, low Ki67), Luminal B (ER and/or PR receptor positive, HER2
positive, or HER2 negative with high Ki67), basal-like tumours (mainly triple-negative
BC) and HER2 positive (ER/PR negative, HER2 positive). Luminal tumours usually
confer good clinical outcome, while the last two subtypes confer shorter relapse free and
overall survival 10, 11. BC also shows heterogeneity in the metabolic reprogramming
including glutamine metabolism. Therefore, understanding the cellular metabolism in
different subtypes will help in identifying potential novel therapeutic targets.
This review highlights the metabolic modulations in breast cancer with emphasis on the role
of altered glutamine metabolism and glutamine transporters in the different molecular
subtypes.
Glutamine metabolism in breast cancer cells
Non-essential amino acids are synthesised endogenously by mammalian cells. However, in
tumour cells they become essential in order to meet the needs of rapid cell growth 12. Glutamine
is the second most essential nutrient used after glucose for driving tumour cell proliferation
and survival 13 with some cancer cells displaying glutamine addiction, to facilitate cell
metabolism and sustain growth. Glutamine can provide the tumour cell with several
mechanisms to achieve this (Figure 1). Firstly, glutamine provides the nitrogen required for the
biosynthesis of nucleotides and non-essential amino acids 14. In addition, glutamine can
replenish the mitochondrial Tricarboxylic acid cycle (TCA) carbon pool via α-ketoglutarate (α-
5KG) synthesis and subsequently, α-KG can undergo reductive carboxylation which supports 
citrate and fatty acid synthesis in stress conditions such as hypoxia 15, 16.
Alternatively, glutamine can be metabolised by glutaminases to provide glutamate. The latter
is a precursor for glutathione (GSH), which is used to reinforce the anti-oxidant response and
maintain the redox balance within cancer cells 17, 18. A further role for glutamine is facilitating
the import of essential amino acids including leucine which maintains activation of the
mammalian target of rapamycin complex1 (mTORC1), which in turn regulates protein
translation and prevents apoptosis in cancer cells 19. Furthermore, in tumours that bear
mutations in isocitrate dehydrogenase (IDH1/ IDH2) such as glioma 20 and cholangiocarcinoma
21, mitochondrial glutamine may be a source for 2 hydroxyglutarate (2HG) which competitively
inhibits α-KG-dependent dioxygenase. If accumulated, 2HG causes aberrations in DNA and 
histone methylation that result in increased stem cell marker expression indicating a switch to
a stem-like phenotype in cancer cells 22, 23. It has been found that 2HG can be accumulated in
MYC driven BC without IDH mutation 24. Both Triple negative (TNBC) and HER2-positive
breast cancer have higher levels of glutamine consumption and glutaminolysis compared with
luminal subtypes 25.
Mutational landscapes control glutamine and glucose metabolism in breast cancer
Glucose and glutamine serves as the primary nutrients to fuel cancer cell proliferation
and indeed the rate of their utilisation far exceed the consumption of other nutrients. It
is been found that the metabolism of these two nutrients is co-regulated as cancer cells
which depend on glycolysis must increase the rate of glutamine consumption to provide
α-KG to the TCA cycle for further production of intermediates required for biosynthetic 
pathways. This reprogramming is controlled by mutations in oncogenes and/or tumour
suppressors or more directly by copy number aberrations of metabolic genes themselves 26.
6The most frequent of these aberrations is TP53 mutations, which occur in approximately 80%
of basal-like and HER2-positive tumours 27. Wild type P53 targets cytochrome C oxidase-2
(SCO2), which promotes aerobic respiration, and TP53-induced glycolysis regulatory
phosphatase (TIGAR), which inhibits glycolysis. Thus, loss of TP53 function shifts
metabolism toward aerobic glycolysis and Warburg metabolism 28, 29. In addition,
mutations in PI3K pathway, which commonly occur in the luminal subtypes of BC, not only
stimulate glycolysis through the growth factor (PI(3)K/Akt/mTOR) signalling pathway
30, it also induces glycolysis through the activation and mobilisation of aldolase A from
the actin cytoskeleton 31.
The oncogene MYC is amplified in approximately 15% of breast cancers particularly in basal-
like tumours, with a lower occurrence in HER2-positive and luminal subtypes 32. MYC is
known to divert glucose metabolism toward aerobic glycolysis and lactate production.
Simultaneously, it has a robust influence in glutamine metabolism as it directly facilitates
glutamine uptake by binding to the promotors and inducing the expression of glutamine
transporters (e.g. SLC1A5 and SLC38A5). It also indirectly promotes the expression of
glutaminase (GLS1) by repressing the expression of miR 23 a/b, miRNAs that repress the
expression of this enzyme 33, 34. Additionally, MYC- driven ER-negative tumours showed
GLS over-expression and 2HG accumulation conferring poor overall survival 24. Glutamine
uptake can be also regulated by Rb family proteins via controlling the E2F-3
transcription factor, which associates with the SLC1A5 promoter and directly regulates
its gene expression where Rb knockout cells exhibit elevated SLC1A5 when compared to
Rb wild type cells 35.
7Metabolic signature in breast cancer varies among different molecular classes
Recently, metabolic profiling of breast tumours has demonstrated a large difference between
malignant and normal breast cells 36, 37 which has been further established within the different
molecular breast cancer subtypes, where ER-negative tumours can be distinguished from those
that are ER-positive depending on their metabolic signatures.
Breast cancer cells have been shown to overexpress glucose transporters and glycolytic
enzymes involved in the metabolic process. For example, Kanaan et al reported an elevated
level of nearly all glycolytic intermediates with strong lactate accumulation in TNBC when
compared to ER-positive tumours. However, there was a slight decrease in citrate observed in
TNBC, indicating an increase in Warburg metabolism, where glucose-derived pyruvate is
shunted to lactate, and citrate is utilised in fatty acid biosynthesis 38-40. Similarly, it has been
reported that the highly invasive MDA-MB-231 (TNBC) cell line has much higher glucose
consumption rates than MCF7 cells (ER-positive, luminal A) 41.
Glutamine dependent mechanisms also can vary substantially among breast cancer subtypes.
TNBCs have increased expression of glutamine metabolic enzymes 42. However, the highest
levels of glutamine metabolism with increased GLS and glutamate dehydrogenase (GLUD)
expression is observed in HER2-positive breast cancer, while luminal A tumours have the
lowest level of these enzymes 25. This is in concordance with higher levels of glutamate and
lower levels of glutamine in TNBC and HER2-positive tumours compared with ER-positive
tumours suggesting an increase in glutamine consumption and glutaminolysis in these tumours
38, 39. Subsequently, glutamine deprivation can reduce the proliferation and progression
especially among the most aggressive types of breast cancer.
8Glutamine transporters and their relevance to breast cancer
In general, all amino acids, including glutamine, require the aid of selective transporters to be
able to cross the plasma membrane. Approximately fourteen amino acid transporters accept
glutamine as a substrate. However, none are solely selective for this amino acid as they also
transport other neutral, cationic and anionic amino acids. Furthermore, they function either in
the influx or efflux of glutamine into/from cells. These transporters belong to four different
gene families; Solute carrier family (SLC) SLC1, SLC6, SLC7, and SLC38; namely SLC1A5,
SLC6A14, SLC6A19, SLC7A5-9, SLC38A1-3, -5, 7-8 [22].
Table 1 summarises the glutamine transporters along with their functions and relevance to
breast cancer.
Reviewing all of the glutamine transporters is beyond the scope of this review, however within
the field of breast cancer metabolism, SLC1A5 and SLC7A5 have been attracting particular
attention due to their role in supporting tumour metabolism and potential as a therapeutic target
within the aggressive sub-classes of BC.
SLC1A5 and SLC7A5 are both expressed in the aggressive subtypes of breast cancer indicating
that the two transporters co-operate at the functional level in promoting tumour growth, as
SLC1A5 maintains the sodium-coupled influx of glutamine, which preserves the biosynthetic
pathway of the rapidly growing cancer cells, whereas SLC7A5 mediates the efflux of this
amino acid in exchange with the influx of leucine, an essential amino acid and potent activator
of mTORC1 (Figure 1).
It is known that c-MYC enhances the expression of SLC1A5 and SLC7A5 through binding to
their promotor regions [39, 40]. Upon glutamine deprivation, activation factor 4 (ATF4), in
coordination with MYC, directly activates the expression of both transporters to maintain
9intracellular levels of amino acids [41, 42]. High expression of SLC1A5 and SLC7A5 was
observed in TN and HER2-positive BC compared with luminal subtypes [20], [43]. Recent
work carried out by our group (data unpublished), have shown that SLC1A5 and SLC7A5
proteins are predominantly expressed in the membrane of the more aggressive ER-positive
luminal B tumours where it confers a poor patient outcome (Figure 2A and 2B). In addition,
cases which exhibited co-expression of both transporters showed a poorer outcome compared
to the single expression of each protein. Indeed SLC7A5 is included, along with other
immunohistochemical markers, in Mammostrat® test, which predicts recurrence rate of early
stage breast cancer patients treated with endocrine therapy 43. In addition, it is shown that this
biomarker, along with carcinoembryonic antigen-related adhesion molecules (CEACAM5 and
CEACAM6), can act as a predictor of poor response to neoadjuvant chemotherapy in locally
advanced breast cancer. Therefore, it will be possible to limit the toxicity of chemotherapy of
non-responder patients 44.
Other glutamine transporters that have been investigated in breast cancer include SLC6A14
and SLC7A8 which are upregulated in ER-positive but not ER-negative breast tumours 45, 46.
In addition, SLC7A7 may be considered a progesterone receptor (PR) target gene, as a study
carried out by Leo et al., showed a 6.5 fold expression change within the TNBC cell line MDA-
MB-231 after PR-transfection 47. Additionally, SLC7A7 along with SLC7A8, SLC7A9 and
SLC38A5 are overexpressed in HER2-positive breast cancer cells line 48. Moreover, SLC38A1
is upregulated and overexpressed in different breast cancer cell lines, particularly those that are
ER-negative, compared with normal breast tissues 49. SLC38A2 has not been investigated in
specific breast cancer subtypes but it has been found to be upregulated by BRCA1 which is
frequently associated with basal-like TNBC 50, 51. Other glutamine transporters have yet to be
studied in breast cancer.
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Metabolic biomarkers can be exploited to predict breast cancer progression and
response to therapy
Various metabolic pathways of cancer cells harbour targets that can be exploited for treatment
of malignant diseases, including breast cancer. These agents can deactivate the essential
pathways which result in lack of energy and the necessary molecules required for cancer cell
growth and survival.
Breast cancer patients with ER-positive and HER2-positive subtypes respond well to endocrine
therapies and anti-HER2 agents respectively. However, some cancers exhibit resistance.
Moreover, conventional chemotherapy remains the main strategy for treating the aggressive
TNBC as there currently lacks targeted therapy for these tumours. Therefore, cellular
metabolism in breast cancer may be promising for developing targeted therapies with fewer
complications and which may also reverse drug resistance. Metabolic approaches including
liquid chromatography-mass spectrometry (LC-MS), gas chromatography-mass spectrometry
(GC-MS) and nuclear magnetic resonance (NMR) spectroscopy, can be applied to analyse
different metabolites in tumour tissue and plasma in order to identify novel diagnostic and
prognostic biomarkers, as well as providing a new anti-cancer agents especially in tumours that
lack response to conventional treatment.
Differences in metabolic signatures between ER-negative and ER-positive breast tumours may
further guide therapy and predict disease outcome. GLS inhibitor CB-839 for example, is
currently being assessed in phase II clinical trials in many solid tumours including in patients
with TNBC 52. Similarly, targeting glutamine transporters in vitro show a considerable
inhibitory effect on these highly aggressive breast cancer cells 42, 53. Interestingly, TNBC cells
are particularly sensitive to the pharmacological inhibition of mTORC1 54. Likewise, a clinical
trial showed that trastuzumab-refractory HER2-positive patients can be actively treated with
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mTORC1 inhibitors combined with anti-HER2 agents 55. Accordingly, targeting SLC1A5 and
SLC7A5 may afford a potential role in treating patients with the most aggressive breast cancer
subtypes through impeding the import of leucine and the subsequent mTORC1 activation.
Thus, designing specific inhibitors, which target this pathway, should be further investigated.
Targeting the transcription factor MYC is another aspect that can be exploited for blocking
cancer metabolism which controls metabolic changes in cancer especially for glutamine import
and catabolism. It has been challenging to target the pleotropic MYC therapeutically. However,
the small molecule inhibitor, CX-3543, that binds G-quadruplexes which exists in the MYC
promoter is currently being tested in phase II clinical trials 56, 57.
Targeting metabolic reprogramming can be potentially useful as a strategy to overcome
resistance to therapy. It is been found that enhanced Warburg metabolism, via
AKT/mTOR/HIF-1α modulations, is one of the mechanisms for deriving tamoxifen 
resistance and impairing glycolysis can restore tamoxifen sensitivity in the endocrine-
resistant BC cells 58. Similarly, Zhao et al found that increased glycolysis in HER2+
cancer cells, through the upregulation of heat shock factor 1 (HSF1) and lactate
dehydrogenase A (LDHA) can participate in trastuzumab resistance, as a combination of
glycolysis inhibitor and the anti-HER2+ drug inhibited the growth of trastuzumab-
resistant breast cancer.
It is important to note that cancer cells exhibit metabolic plasticity which allow them to survive
and grow under unfavourable and stressful environments, making this character a major issue
facing metabolic targeting of cancer cells. Targeting a particular metabolic pathway may not
be sufficient as a viable strategy for cancer treatment as tumour cells could develop resistance
through expressing other alternative pathways. For example, metastatic breast cancer shows
striking plasticity to adapt their metabolism and growth under different conditions.
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To allow exposing to microenvironmental changes which better represent invivo systems,
Magnetic Resonance Spectroscopy (MRS) was applied, by Simões et al, in a high-density
3D invitro model. They observed that under glutamine starvation, metastatic breast cancer
cells (4T1) showed increased pyruvate carboxylase activity, which catalyses the carboxylation
of pyruvate to form oxaloacetate (OAA), while glutamine supply can cause decrease in the
activity of this enzyme, as more glutamine is available to replenish the TCA cycle at the level
of OAA. This indicates the presence of an alternative pathway into the TCA cycle driven by
glutamine and independent of glucose 59. Therefore, to obtain a more effective anti-cancer
therapy of metastatic breast cancer, both pathways, glycolysis and oxidative phosphorylation,
should be targeted. In addition, it can be suggested that the synergistic lethality targeting both
glutamine and glucose pathways may prove to be more effective in the treatment of cancer,
taking into account the toxic effect of these on normal cells, otherwise this treatment regime
may be accompanied with the same types of toxicity caused by conventional chemotherapy.
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Conclusion
Breast cancer exhibits disparity among their molecular classes for the relative importance of
metabolic pathways. The most prominent is the aggressive metabolic pattern of TNBC and the
changes in the glutamine pathway. Studying the metabolic pathways of these breast cancer
subtypes can lead to the discovery of candidate biomarkers as well as providing novel agents
which can guide to a personalised treatment. Designing metabolic targeting agents with a
synergistic lethality may prove to be more effective in cancer treatment. Overall, the integration
of metabolomic characteristics of breast cancer with genomic, transcriptomic, and proteomic
data is a way forward towards a more comprehensive understanding of the disease progression
and response to therapy.
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Table1. Glutamine transporters, their functions and relevance to breast cancer
Transporter Function Observations in different BC subtypes
SLC1A5 Glutamine influx/efflux
 Expressed mainly in HER2+ and
TNBC
 Inhibition or knockdown of
SLC1A5 decreased tumour cell
growth in basal-like cells
(HCC1806) in vitro and in vivo,
while the growth of MCF7 was
unaffected 42.
SLC7A5 Glutamine influx/efflux
 Expressed mainly in HER2+ and
TNBC.
 Applying SLC7A5 inhibitor BCH
or knockdown significantly
inhibits MDA-MB-231 cell growth
53.
SLC6A14 Glutamine influx
 Up-regulated in ER+ve BC
 Treatment with SLC6A14
inhibitor, α-methyl-DL-tryptophan 
(α-MT), reduced ZR-75-1 cell 
growth, while it did not affect the
growth of MDA-MB-23145
SLC7A8 Glutamine efflux
 Up regulated in ER+ve breast cancer
and it has the same amino acid
substrate like SLC7A5. However, it
exhibits relatively lower affinity.
SLC38A1 Glutamine influx
 SLC38A1 is upregulated and
overexpressed in ER-ve cell lines
 Knockdown of SLC38A1 reduce
cell growth of the mouse breast
cancer cell line (4T1) 49

SLC7A7
SLC7A9
SLC38A5
Glutamine influx
Glutamine efflux
Glutamine influx/efflux
 Overexpressed in HER2 positive
breast cancer cell lines.
SLC7A6
SLC38A2
SLC38A3
SLC38A7
SLC38A8
Glutamine influx
Glutamine influx
Glutamine influx/efflux
Glutamine influx
Glutamine influx
 Have yet to be studied in breast
cancer
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Figure legends
Figure1. Role of glutamine in supporting tumour growth
Key: GLUT, Glucose transporter; SLC1A5, Solute carrier family 5 member1; SLC7A5, Solute carrier family 7
member 5; TCA. Tricarboxylic acid cycle; AC-coA, Acetyl coenzyme A; OAA, Oxaloacetate; α-KG, α-
Ketoglutarate, LDH, Lactate dehydrogenase; GLS, Glutaminase; GLUD, Glutamate dehydrogenase; mTORC1,
mammalian target of rapamycin complex1; 2HG, 2 Hydroxyglutarate.
Glucose and glutamine are the two essential metabolites used to fuel cancer cells. Glutamine plays an essential
role in supporting cancer cell growth. Glutamine can act as a nitrogen donor and assist nucleotide biosynthesis
and the synthesis of other essential amino acids. Additionally, Glutamine can be metabolised by glutaminases to
provide glutamate. The latter, is a precursor for glutathione, which neutralises the reactive oxygen species (ROS).
Furthermore, glutamate can be converted to α-KG, which is used to replenish the TCA cycle. α-KG can also be a 
precursor for the oncometabolite (2HG), which causes methylation specific changes and increases the expression
of stem cell markers. Glucose and glutamine are the two essential metabolites used to fuel cancer cells. Glutamine
is imported into the cells through glutamine transporters (e.g. SLC1A5) and its efflux is coupled by influx of
leucine, through SLC7A5, The amino acid which activates mTORC1 and subsequently supports cancer cell
proliferation.
Figure 2. Immunohistochemical expression of SLC1A5 and SLC7A5 in invasive BC
Positive cytomembranous immunoreactivity of glutamine transporters in invasive breast cancer cores. A)
SLC7A5, B) SLC1A5.
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